Colorectal cancer (CRC), as a prominent cause of cancer-related deaths, has historically
been notable worldwide and many attempts have been made to raise the overall survival of …

Marching into the second decade after the approval of ipilimumab, it is clear that immune
checkpoint inhibitors (ICIs) have dramatically improved the prognosis of melanoma …

Acquired resistance to immunotherapy remains a critical yet incompletely understood
biological mechanism. Here, using a mouse model of pancreatic ductal adenocarcinoma …

Nivolumab, an anti–programmed death-1 (PD-1) monoclonal antibody, showed promising
activity in relapsed or refractory (R/R) follicular lymphoma (FL) in a phase 1 study. We …

Mounting an effective immune response against cancer requires the activation of innate and
adaptive immune cells. Metastatic melanoma is the most aggressive form of skin cancer …

Recent advances in our understanding of the dynamics of cellular cross-talk have
highlighted the significance of host-versus-tumor effect that can be harnessed with immune …

Immune checkpoint inhibitors (ICIs) have demonstrated to be highly efficient in treating solid
tumors; however, many patients have limited benefits in terms of response and survival. This …

Objectives Treatment of non-small cell lung cancer (NSCLC) with immune checkpoint
blockade (ICB) has resulted in striking clinical responses, but only in a subset of patients …

The functional decline in T cells during their chronic stimulation, commonly referred to as T
cell exhaustion, is a major limitation for current immunotherapy approaches. As modern …

Tissue-resident memory T cells (TRM cells) have become an interesting subject of study for
antitumor immunity in melanoma and other solid tumors. In the initial phases of antitumor …